Patents Assigned to Novartis AG
  • Compositions, methods, and therapeutic uses related to fusogenic protein minion
    Patent number: 11339209
    Abstract: The invention provides novel compositions, methods, and therapeutic uses related to fusogenic protein MINION (microprotein inducer of fusion).
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: May 24, 2022
    Assignee: NOVARTIS AG
    Inventors: Stephane Corbel, Srihari Cidambi Sampath, Srinath Cidambi Sampath, Christian Schmedt, Qiao Zhang
  • Compounds and compositions for treating conditions associated with NLRP activity
    Patent number: 11339136
    Abstract: In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: May 24, 2022
    Assignee: Novartis AG
    Inventors: Gary Glick, Shomir Ghosh, William R. Roush
  • OPTIMIZED LENTIVIRAL TRANSFER VECTORS AND USES THEREOF
    Publication number: 20220145326
    Abstract: The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and/or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.
    Type: Application
    Filed: November 23, 2021
    Publication date: May 12, 2022
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Vladimir SLEPUSHKIN, Dmitriy LUKASHEV
  • Medical container with NFC antenna
    Patent number: 11324661
    Abstract: A pharmaceutical container includes a cylindrical hollow container body defining a hollow chamber to receive a pharmaceutical liquid, the container body including a portion on a sidewall) of the container body, wherein the portion has a longitudinal extension along the longitudinal axis of the container body and a circumferential extension along the circumference of the container body, thereby forming a window through the sidewall of the container body into the hollow chamber. In embodiments of the invention, the window comprises two long edges and two short edges, and a Near Field Communication (NFC) antenna. In embodiments of the invention, the antenna comprises one or a plurality of nested antenna windings.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: May 10, 2022
    Assignee: Novartis AG
    Inventors: Andrew Bryant, Alain Schmidlin, Daniel Latham, Gabriel Iobbi, Arun Venkatasubramanian, Thomas Richard Redman, Timothy Duncan Wooller, Franck Rubiconi, Robert George Milner, Richard Andrew Hall, Symon Cotton, Simon Peter Attard
  • Use of alpha 7 nicotinic acetylcholine receptor agonists
    Patent number: 11311525
    Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 26, 2022
    Assignee: Novartis AG
    Inventors: Markus Fendt, Dominik Feuerbach, Sjoerd Johannes Finnema, Christer Halldin, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Judit Sovago, Markus Weiss
  • Antibody molecules to CD73 and uses thereof
    Patent number: 11312783
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: April 26, 2022
    Assignees: Novartis AG, SURFACE ONCOLOGY, INC.
    Inventors: Bianka Prinz, Jerry M. Thomas, Ansgar Brock, Scott Chappel, Andrew Lake, Alison Paterson, Rachel W. O'Connor, Michael Warren, Pamela Holland, Dirksen Bussiere, Mikias Woldegiorgis, Wei Shu, John Delmas Venable, Michael Gladstone, Jonathan Hill, Christine Miller
  • Antibodies against growth differentiation factor 15 and uses thereof
    Patent number: 11312766
    Abstract: Provided herein are monoclonal antibodies (e.g., human antibodies) binding to human Growth Differentiation Factor 15 protein (hereinafter, sometimes referred to as “GDF15”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: April 26, 2022
    Assignee: NOVARTIS AG
    Inventors: Hong Chen, Rajiv Chopra, Seung Wan Hahm, Norio Hamamatsu, Ryan Scott Streeper, Mei Xu
  • Methods for making conjugates from disulfide-containing proteins
    Patent number: 11311400
    Abstract: The invention provides methods to prepare protein conjugates from proteins having at least two cysteines. In one embodiment, a protein with a disulfide linkage is reduced to provide two free cysteines for reaction with a 1,3-dihaloacetone or similar reactant, linking the sulfur atoms of the two cysteines together. The ketone inserted between the sulfur atoms is then used to form a Schiff base to an aminated payload molecule, thus conjugating the protein to a payload. In another embodiment, two cysteine residues are tied together by reaction with a 1,3-dihaloacetone or similar reactant. The linkage between the sulfur atoms in each case holds the protein or peptide in a constrained conformation, while also providing a convenient place for attaching a payload with good specificity and efficiency.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: April 26, 2022
    Assignee: Novartis AG
    Inventors: Qi-Ying Hu, Hidetomo Imase
  • Pharmaceutical compositions containing a DGAT1 inhibitor
    Patent number: 11304907
    Abstract: The present invention relates to a pharmaceutical composition comprising a) a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, b) one or more, e.g. 1, 2 or 3, surfactants with lubricant properties; c) one or more, e.g. 1, 2 or 3, dry binders with disintegrant properties; d) one or more, e.g. 1, 2 or 3, fillers, and e) one or more, e.g. 1, 2 or 3, disintegrants.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: April 19, 2022
    Assignee: Novartis AG
    Inventors: Hong Wen, Natrajan Kumaraperumal, Richard Nause
  • Pharmaceutical composition
    Patent number: 11291661
    Abstract: The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising an (a) inert substrate and a (b) mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: April 5, 2022
    Assignee: Novartis AG
    Inventors: Geoffrey Gogniat, Saran Kumar, Ulrich Meier, Mario Rentsch
  • Selective reduction of cysteine residues in IL-17 antibodies
    Patent number: 11292833
    Abstract: The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL-17 antibodies or antigen binding fragments thereof (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX).
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: April 5, 2022
    Assignee: NOVARTIS AG
    Inventors: Markus Heitzmann, Johann Winkler
  • Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
    Patent number: 11278618
    Abstract: The present disclosure relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits for inhibiting the progression of structural damage in psoriatic arthritis (PsA) patients using Interleukin-17 (IL-17) antagonists, e.g., IL-17 antibodies and antigen-binding fragments thereof, e.g., secukinumab.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: March 22, 2022
    Assignee: NOVARTIS AG
    Inventors: Shephard Mpofu, Hanno Richards, Gregory Ligozio
  • Diamino pyridine derivatives
    Patent number: 11274080
    Abstract: The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: March 15, 2022
    Assignee: Novartis AG
    Inventor: Gebhard Thoma
  • Combination therapy
    Patent number: 11266653
    Abstract: The present invention relates to a pharmaceutical combination comprising (a) a Raf inhibitor as defined herein, or a pharmaceutically acceptable salt thereof and (b) a MEK inhibitor, particularly trametinib, particularly for use in the treatment of a proliferative disease. This invention also relates to uses of such combination for preparation of a medicament for the treatment of a proliferative disease; methods of treating a proliferative disease in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; use of such combination for the treatment of proliferative disease; pharmaceutical compositions comprising such combination and commercial packages thereto.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: March 8, 2022
    Assignee: NOVARTIS AG
    Inventor: Vesselina Cooke
  • Apparatus and method for producing a flow profile
    Patent number: 11266347
    Abstract: A method for generating a flow profile of an inhalation device is described. The method comprises the step of measuring acoustic emissions induced by inhalation flow through the inhalation device. The method further comprises the step of detecting peak frequencies in the measured acoustic emissions and generating a flow profile based on the detected peak frequencies. A corresponding device is also described.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 8, 2022
    Assignee: Novartis AG
    Inventors: Peter Matthewson, Laure Mahé
  • NLRP3 inflammasome inhibitors
    Patent number: 11254653
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: February 22, 2022
    Assignee: Novartis AG
    Inventors: Christopher Farady, Nina Gommermann, Philipp Janser, Angela Mackay, Henri Mattes, Nichola Smith, Catherine Fooks Solovay, Nikolaus Johannes Stiefl, Eric Vangrevelinghe, Juraj Velcicky, Anette von Matt
  • Computer method and system for deriving cell-to-cell spatial proximities
    Patent number: 11249066
    Abstract: The invention relates, in part, to systems and methods for scoring a sample containing tumor tissue from a cancer patient. The score is representative of a nearness between at least one pair of cells, a first member of the least one pair of cells expressing a first biomarker and a second member of the at least one pair of cells expressing a second biomarker that is different from the first biomarker. The score obtained from these methods can be indicative of a likelihood that a patient may respond positively to immunotherapy.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: February 15, 2022
    Assignee: Novartis AG
    Inventors: Brian Little, Jennifer Bordeaux
  • Mesenchymal stem cell differentiation
    Patent number: 11241482
    Abstract: The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: February 8, 2022
    Assignees: NOVARTIS AG, The Scripps Research Institute
    Inventors: Lori Jennings, Kristen Johnson, Peter Schultz
  • Eukaryotic cells and methods for recombinantly expressing a product of interest
    Patent number: 11242551
    Abstract: The disclosure pertains to novel eukaryotic cell suitable for recombinant production of a product of interest, wherein the genome of the host cell is altered so that the effect of protein FAM60A is impaired in said cell, e.g. by reducing or eliminating functional expression of gene FAM60A thereby improving the stability characteristics. Furthermore, the present disclosure provides associated technologies wherein such host cells are used in recombinant production technologies.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: February 8, 2022
    Assignee: Novartis AG
    Inventors: Thomas Jostock, Holger Laux, Anett Ritter
  • Glycoside derivatives and uses thereof
    Patent number: RE49080
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: May 24, 2022
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang